497
Participants
Start Date
February 28, 2023
Primary Completion Date
October 31, 2024
Study Completion Date
October 31, 2024
Bivalent Moderna
A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
Novavax
A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne
Lead Sponsor
Coalition for Epidemic Preparedness Innovations
OTHER
The Peter Doherty Institute for Infection and Immunity
OTHER
Murdoch Childrens Research Institute
OTHER